MedKoo Cat#: 598223 | Name: Lactitol
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lactitol is a gastrointestinal agent. Lactitol is an analog of the disaccharide alcohol, lactulose. It is used as a laxative in the treatment of constipation. This unabsorbable lactose derivative has attracted interest as a sweetener for low-calorie foods.

Chemical Structure

Lactitol
Lactitol
CAS#585-86-4 (free)

Theoretical Analysis

MedKoo Cat#: 598223

Name: Lactitol

CAS#: 585-86-4 (free)

Chemical Formula: C12H24O11

Exact Mass: 344.1319

Molecular Weight: 344.31

Elemental Analysis: C, 41.86; H, 7.03; O, 51.11

Price and Availability

Size Price Availability Quantity
100mg USD 450.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Synonym
Lactitol; Lactit; Lactosit Miruhen; NSC 231323; NSC-231323; NSC231323;
IUPAC/Chemical Name
(2S,3R,4R,5R)-4-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)hexane-1,2,3,5,6-pentaol
InChi Key
VQHSOMBJVWLPSR-JVCRWLNRSA-N
InChi Code
InChI=1S/C12H24O11/c13-1-4(16)7(18)11(5(17)2-14)23-12-10(21)9(20)8(19)6(3-15)22-12/h4-21H,1-3H2/t4-,5+,6+,7+,8-,9-,10+,11+,12-/m0/s1
SMILES Code
OC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O[C@H]1[C@@H]([C@H]([C@H]([C@@H](CO)O1)O)O)O)O)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info
Product Data
Biological target:
Lactitol (D-Lactitol), a nonabsorbable disaccharide, has the potential for constipation research.
In vitro activity:
The results of this screening study indicate that xylo-oligosaccharides and lactitol support the growth of a limited number of beneficial microbes in pure cultures. Reference: Benef Microbes. 2010 Jun;1(2):139-48. https://pubmed.ncbi.nlm.nih.gov/21840802/
In vivo activity:
Ingestion of lactitol significantly increased the acute postprandial PYY response in rats, and prolonged consumption decreased weight gain in growing rats. Reference: Nutrition. 2005 Oct;21(10):1036-43. https://pubmed.ncbi.nlm.nih.gov/16157241/
Solvent mg/mL mM
Solubility
DMSO 68.0 197.49
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 344.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Mäkeläinen H, Saarinen M, Stowell J, Rautonen N, Ouwehand AC. Xylo-oligosaccharides and lactitol promote the growth of Bifidobacterium lactis and Lactobacillus species in pure cultures. Benef Microbes. 2010 Jun;1(2):139-48. doi: 10.3920/BM2009.0029. PMID: 21840802. 2. Gee JM, Johnson IT. Dietary lactitol fermentation increases circulating peptide YY and glucagon-like peptide-1 in rats and humans. Nutrition. 2005 Oct;21(10):1036-43. doi: 10.1016/j.nut.2005.03.002. PMID: 16157241.
In vitro protocol:
1. Mäkeläinen H, Saarinen M, Stowell J, Rautonen N, Ouwehand AC. Xylo-oligosaccharides and lactitol promote the growth of Bifidobacterium lactis and Lactobacillus species in pure cultures. Benef Microbes. 2010 Jun;1(2):139-48. doi: 10.3920/BM2009.0029. PMID: 21840802.
In vivo protocol:
1. Gee JM, Johnson IT. Dietary lactitol fermentation increases circulating peptide YY and glucagon-like peptide-1 in rats and humans. Nutrition. 2005 Oct;21(10):1036-43. doi: 10.1016/j.nut.2005.03.002. PMID: 16157241.
1: Miller LE, Tennilä J, Ouwehand AC. Efficacy and tolerance of lactitol supplementation for adult constipation: a systematic review and meta-analysis. Clin Exp Gastroenterol. 2014 Jul 12;7:241-8. doi: 10.2147/CEG.S58952. eCollection 2014. Review. PubMed PMID: 25050074; PubMed Central PMCID: PMC4103919. 2: Olli K, Saarinen MT, Forssten SD, Madetoja M, Herzig KH, Tiihonen K. Independent and Combined Effects of Lactitol, Polydextrose, and Bacteroides thetaiotaomicron on Postprandial Metabolism and Body Weight in Rats Fed a High-Fat Diet. Front Nutr. 2016 Jun 8;3:15. doi: 10.3389/fnut.2016.00015. eCollection 2016. PubMed PMID: 27376068; PubMed Central PMCID: PMC4896914. 3: Morimoto K, Shimonishi T, Miyake S, Takata G, Izumori K. Preparation of D-gulose from disaccharide lactitol using microbial and chemical methods. Biosci Biotechnol Biochem. 2013;77(2):253-8. Epub 2013 Feb 7. PubMed PMID: 23391912. 4: Gluud LL, Vilstrup H, Morgan MY. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2016 May 6;(5):CD003044. doi: 10.1002/14651858.CD003044.pub4. Review. PubMed PMID: 27153247. 5: Chen C, Yu X, Lu H, Xiao D, Mao W, Li L. Antioxidant protective effects of lactitol against endotoxemia in patients with chronic viral hepatitis. Mol Med Rep. 2013 Feb;7(2):401-5. doi: 10.3892/mmr.2012.1188. Epub 2012 Nov 16. PubMed PMID: 23165913. 6: Gluud LL, Vilstrup H, Morgan MY. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2016 Apr 18;4:CD003044. doi: 10.1002/14651858.CD003044.pub3. Review. Update in: Cochrane Database Syst Rev. 2016;(5):CD003044. PubMed PMID: 27089005. 7: Maydeo A. Lactitol or lactulose in the treatment of chronic constipation: result of a systematic. J Indian Med Assoc. 2010 Nov;108(11):789-92. Review. PubMed PMID: 21510584. 8: Mäkivuokko H, Forssten S, Saarinen M, Ouwehand A, Rautonen N. Synbiotic effects of lactitol and Lactobacillus acidophilus NCFM™ in a semi-continuous colon fermentation model. Benef Microbes. 2010 Jun;1(2):131-7. doi: 10.3920/BM2009.0033. PubMed PMID: 21840801. 9: Finney M, Smullen J, Foster HA, Brokx S, Storey DM. Effects of low doses of lactitol on faecal microflora, pH, short chain fatty acids and gastrointestinal symptomology. Eur J Nutr. 2007 Sep;46(6):307-14. Epub 2007 Jul 11. PubMed PMID: 17623227. 10: Majumder A, Sultan A, Jersie-Christensen RR, Ejby M, Schmidt BG, Lahtinen SJ, Jacobsen S, Svensson B. Proteome reference map of Lactobacillus acidophilus NCFM and quantitative proteomics towards understanding the prebiotic action of lactitol. Proteomics. 2011 Sep;11(17):3470-81. doi: 10.1002/pmic.201100115. Epub 2011 Jul 27. PubMed PMID: 21751373. 11: Chen C, Li L, Wu Z, Chen H, Fu S. Effects of lactitol on intestinal microflora and plasma endotoxin in patients with chronic viral hepatitis. J Infect. 2007 Jan;54(1):98-102. Epub 2006 Oct 16. PubMed PMID: 17049992. 12: Patil DH, Grimble GK, Silk DB. Lactitol, a new hydrogenated lactose derivative: intestinal absorption and laxative threshold in normal human subjects. Br J Nutr. 1987 Mar;57(2):195-9. PubMed PMID: 3552029. 13: Riggio O, Balducci G, Ariosto F, Merli M, Tremiterra S, Ziparo V, Capocaccia L. Lactitol in the treatment of chronic hepatic encephalopathy--a randomized cross-over comparison with lactulose. Hepatogastroenterology. 1990 Oct;37(5):524-7. PubMed PMID: 2253931. 14: Copé R, Debou JM, Cohen S, Callens A. [Study of early postoperative lactitol versus paraffin following anal surgery in 110 adult patients]. Ann Chir. 1996;50(7):570-6. French. PubMed PMID: 9035428. 15: Grenby TH, Phillips A. Dental and metabolic effects of lactitol in the diet of laboratory rats. Br J Nutr. 1989 Jan;61(1):17-24. PubMed PMID: 2923853. 16: Cammà C, Fiorello F, Tinè F, Marchesini G, Fabbri A, Pagliaro L. Lactitol in treatment of chronic hepatic encephalopathy. A meta-analysis. Dig Dis Sci. 1993 May;38(5):916-22. PubMed PMID: 8482191. 17: Uribe M, Toledo H, Perez F, Vargas F, Gil S, Garcia-Ramos G, Ravelli GP, Guevara L. Lactitol, a second-generation disaccharide for treatment of chronic portal-systemic encephalopathy. A double-blind, crossover, randomized clinical trial. Dig Dis Sci. 1987 Dec;32(12):1345-53. PubMed PMID: 3319453. 18: Natah SS, Hussien KR, Tuominen JA, Koivisto VA. Metabolic response to lactitol and xylitol in healthy men. Am J Clin Nutr. 1997 Apr;65(4):947-50. PubMed PMID: 9094877. 19: Soontornchai S, Sirichakwal P, Puwastien P, Tontisirin K, Krüger D, Grossklaus R. Lactitol tolerance in healthy Thai adults. Eur J Nutr. 1999 Oct;38(5):218-26. PubMed PMID: 10654158. 20: Heredia D, Terés J, Orteu N, Rodés J. Lactitol vs. lactulose in the treatment of chronic recurrent portal-systemic encephalopathy. J Hepatol. 1988 Aug;7(1):106-10. PubMed PMID: 3053887.